CLOVER BIO-B(02197): Recruitment of subjects for Australian phase II clinical trial of respiratory syncytial virus (RSV) + human metapneumovirus (hMPV) + parainfluenza virus type 3 (PIV3) respiratory co-vaccine candidate product.

CLOVER BIO-B (02197) announces that the recruitment for the Australian Phase II clinical trial of the company's proprietary respiratory syncytial virus (RSV) combined vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV + hMPV + PIV3) has been completed. Based on Clover Biopharmaceuticals' verified trimeric protein (Trimer-Tag) vaccine technology platform, the company's RSV respiratory combined vaccine candidates utilize fusion pre-F (Pre-F) trimeric subunit vaccine protein antigens. The ongoing Phase II clinical trial of Clover Biopharmaceuticals' RSV combined vaccine candidates is a randomized, observer-blind, multicenter study recruiting 420 elderly subjects (60-85 years old) in Australia, who are randomly allocated to receive SCB-1022, SCB-1033, or placebo. This clinical trial assesses the safety, reactogenicity, and immunogenicity of the company's RSV combined vaccine candidates, with preliminary results expected in the third quarter of 2026.